<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37743411</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-3635</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Signal transduction and targeted therapy</Title><ISOAbbreviation>Signal Transduct Target Ther</ISOAbbreviation></Journal><ArticleTitle>Secreted LRPAP1 binds and triggers IFNAR1 degradation to facilitate virus evasion from cellular innate immunity.</ArticleTitle><Pagination><StartPage>374</StartPage><MedlinePgn>374</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">374</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41392-023-01630-1</ELocationID><Abstract><AbstractText>The crucial role of interferon (IFN) signaling is well known in the restriction or eradication of pathogen invasion. Viruses take a variety of ways to antagonize host defense through eliminating IFN-signaling intracellularly for decades. However, the way by viruses target IFN-signaling extracellularly has not been discovered. Infection by both coronavirus SARS-CoV-2 and enterovirus 71 (EV71 or EV-A71) can cause severe diseases such as neurological disorders and even death in children.<sup>1-3</sup> Here, we show evidence that the protease of SARS-CoV-2 (3CL<sup>pro</sup>) and EV71 (2A<sup>pro</sup>) upregulates the expression and secretion of LDL-receptor-related protein-associated protein 1 (LRPAP1). As a ligand, the N-terminus of secreted LRPAP1 binds with the extracellular domain of IFNAR1 that triggers the receptor ubiquitination and degradation and promotes virus infection both in vitro, ex vivo in the mouse brain, and in vivo in newborn mice. A small peptide from the N-terminus of LRPAP1 effectively binds and causes IFNAR1 degradation that enhances both DNA and RNA viral infections, including herpesvirus HSV-1, hepatitis B virus (HBV), EV71, and beta-coronavirus HCoV-OC43; whereas α2M, a LRPAP1 inhibitor, arrests virus infections by stabilizing IFNAR1. Our study demonstrates a new mechanism used by viruses for evading host cell immunity, supporting a strategy for developing pan-antiviral drugs.</AbstractText><CopyrightInformation>© 2023. West China Hospital, Sichuan University.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Huangcan</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1409-9219</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CityU Shenzhen Research Institute, Nanshan, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Xiong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Yiran</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yichen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Yin-Ting</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jufang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ming-Liang</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China. minglihe@cityu.edu.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CityU Shenzhen Research Institute, Nanshan, Shenzhen, China. minglihe@cityu.edu.hk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Signal Transduct Target Ther</MedlineTA><NlmUniqueID>101676423</NlmUniqueID><ISSNLinking>2059-3635</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C507964">IFNAR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>156986-95-7</RegistryNumber><NameOfSubstance UI="D053633">Receptor, Interferon alpha-beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053633" MajorTopicYN="N">Receptor, Interferon alpha-beta</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>M.L.H., H.L. and X.W. are inventors of US patent application no. 63/500,277 in May 2023. Title: Method of use LRPAP1 inhibitors against multiple virus infections. The others declare no competing interests. M.L.H. is one of the editorial board members in <i>Signal Transduction and Targeted Therapy</i> and he has not been involved in the process of the manuscript handling.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>24</Day><Hour>23</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37743411</ArticleId><ArticleId IdType="pmc">PMC10518340</ArticleId><ArticleId IdType="doi">10.1038/s41392-023-01630-1</ArticleId><ArticleId IdType="pii">10.1038/s41392-023-01630-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>LaRovere KL, et al. Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol. 2021;78:536–547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7936352</ArticleId><ArticleId IdType="pubmed">33666649</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray STJ, et al. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc. Health. 2021;5:631–641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279959</ArticleId><ArticleId IdType="pubmed">34273304</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778–790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasteiger G, et al. Cellular innate immunity: an old game with new players. J. Innate Immun. 2017;9:111–125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6738785</ArticleId><ArticleId IdType="pubmed">28006777</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi O, Akira S. Innate immunity to virus infection. Immunol. Rev. 2009;227:75–86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5489343</ArticleId><ArticleId IdType="pubmed">19120477</ArticleId></ArticleIdList></Reference><Reference><Citation>Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449:819–826.</Citation><ArticleIdList><ArticleId IdType="pubmed">17943118</ArticleId></ArticleIdList></Reference><Reference><Citation>Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.</Citation><ArticleIdList><ArticleId IdType="pubmed">16497588</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutler B, et al. Genetic analysis of resistance to viral infection. Nat. Rev. Immunol. 2007;7:753–766.</Citation><ArticleIdList><ArticleId IdType="pubmed">17893693</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, et al. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host microbe. 2009;5:72–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2741731</ArticleId><ArticleId IdType="pubmed">19154989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampron A, ElAli A, Rivest S. Innate Immunity in the CNS: redefining the relationship between the CNS and its environment. Neuron. 2013;78:214–232.</Citation><ArticleIdList><ArticleId IdType="pubmed">23622060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini A, et al. Innate and adaptive immune responses against coronavirus. Biomed. Pharmacother. 2020;132:110859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7580677</ArticleId><ArticleId IdType="pubmed">33120236</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, et al. Enterovirus 2Apro Targets MDA5 and MAVS in infected cells. J. Virol. 2014;88:3369–3378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3957915</ArticleId><ArticleId IdType="pubmed">24390337</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, et al. Main protease of SARS-CoV-2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling. Signal Transduct. Target Ther. 2020;5:221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537955</ArticleId><ArticleId IdType="pubmed">33024073</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesev EV, LeDesma RA, Ploss A. Decoding type I and III interferon signalling during viral infection. Nat. Microbiol. 2019;4:914–924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554024</ArticleId><ArticleId IdType="pubmed">30936491</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro JR, et al. S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification. PNAS. 2016;113:1351–1356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4747766</ArticleId><ArticleId IdType="pubmed">26787880</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, et al. Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1. J. Virol. 2012;86:3767–3776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302529</ArticleId><ArticleId IdType="pubmed">22258259</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldahmesh MA, et al. Mutations in LRPAP1 are associated with severe myopia in humans. Am. J. Hum. Genet. 2013;93:313–320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3738831</ArticleId><ArticleId IdType="pubmed">23830514</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey P, Pradhan S, Mittal B. LRP-associated protein gene (LRPAP1) and susceptibility to degenerative dementia. Genes Brain Behav. 2008;7:943–950.</Citation><ArticleIdList><ArticleId IdType="pubmed">18721259</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad JM, Migliorini M, Galisteo R, Strickland DK. Generation of a potent low density lipoprotein receptor-related Protein 1 (LRP1) antagonist by engineering a stable form of the receptor-associated protein (RAP) D3 domain. J. Biol. Chem. 2015;290:17262–17268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4498065</ArticleId><ArticleId IdType="pubmed">26013822</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond DL, et al. Temporal proteome and lipidome profiles reveal Hepatitis C Virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog. 2010;6:e1000719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796172</ArticleId><ArticleId IdType="pubmed">20062526</ArticleId></ArticleIdList></Reference><Reference><Citation>An FQ, et al. The latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. J. Biol. Chem. 2005;280:3862–3874.</Citation><ArticleIdList><ArticleId IdType="pubmed">15525642</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science. 1994;264:1471–1474.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515194</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian W, et al. Low-density-lipoprotein-receptor-related protein 1 mediates Notch pathway activation. Dev. Cell. 2021;56:2902–2919.e2908.</Citation><ArticleIdList><ArticleId IdType="pubmed">34626540</ArticleId></ArticleIdList></Reference><Reference><Citation>Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022;375:267–269.</Citation><ArticleIdList><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei J, Hilgenfeld R. RNA-virus proteases counteracting host innate immunity. FEBS Lett. 2017;591:3190–3210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163997</ArticleId><ArticleId IdType="pubmed">28850669</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews K, Schäfer A, Pham A, Frieman M. The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity. Virol. J. 2014;11:209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272517</ArticleId><ArticleId IdType="pubmed">25481026</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 2021;19:685–700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8447893</ArticleId><ArticleId IdType="pubmed">34535791</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, Lu J, Kung HF, He ML. The virology and developments toward control of human enterovirus 71. Crit. Rev. Microbiol. 2011;37:313–327.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651436</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya S, et al. Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol. Med. 2014;6:384–397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3958312</ArticleId><ArticleId IdType="pubmed">24480543</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya S, et al. Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor. J. Biol. Chem. 2011;286:22069–22076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121351</ArticleId><ArticleId IdType="pubmed">21540188</ArticleId></ArticleIdList></Reference><Reference><Citation>Chmiest D, et al. Spatiotemporal control of interferon-induced JAK/STAT signalling and gene transcription by the retromer complex. Nat. Commun. 2016;7:13476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5150223</ArticleId><ArticleId IdType="pubmed">27917878</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Sastre A. Ten strategies of interferon evasion by viruses. Cell Host microbe. 2017;22:176–184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576560</ArticleId><ArticleId IdType="pubmed">28799903</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale M, Jr, Sen GC. Viral evasion of the interferon system. J. Interferon Cytokine Res. 2009;29:475–476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3016867</ArticleId><ArticleId IdType="pubmed">19694549</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova J-L, Abel L. Mechanisms of viral inflammation and disease in humans. Science. 2021;374:1080–1086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8697421</ArticleId><ArticleId IdType="pubmed">34822298</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat. Rev. Immunol. 2020;20:397–398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7249038</ArticleId><ArticleId IdType="pubmed">32457522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, et al. Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus. Mol. Cell Proteom. 2009;8:2582–2594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773723</ArticleId><ArticleId IdType="pubmed">19671925</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Z, Prorok M, Brown BE, Castellino FJ. N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein. Neuropharmacology. 2008;55:204–214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2610414</ArticleId><ArticleId IdType="pubmed">18602124</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantuano E, et al. LDL receptor-related protein-1 regulates NFkappaB and microRNA-155 in macrophages to control the inflammatory response. PNAS. 2016;113:1369–1374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4747752</ArticleId><ArticleId IdType="pubmed">26787872</ArticleId></ArticleIdList></Reference><Reference><Citation>Galliano MF, et al. Binding of alpha2ML1 to the low density lipoprotein receptor-related protein 1 (LRP1) reveals a new role for LRP1 in the human epidermis. PLoS One. 2008;3:e2729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2453322</ArticleId><ArticleId IdType="pubmed">18648652</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow T, Goldstein J, Orth K, Brown M, Herz J. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J. Biol. Chem. 1993;267:26172–26180.</Citation><ArticleIdList><ArticleId IdType="pubmed">1464627</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Q, et al. Hsc70 regulates the IRES activity and serves as an antiviral target of enterovirus A71 infection. Antivir. Res. 2018;150:39–46.</Citation><ArticleIdList><ArticleId IdType="pubmed">29180285</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, et al. Pim1 impacts enterovirus A71 replication and represents a potential target in antiviral therapy. iScience. 2019;19:715–727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726883</ArticleId><ArticleId IdType="pubmed">31476618</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan S, Xu Z, Liu P, Qin Y, Chen M. Enterovirus 71 2A protease inhibits P-body formation to promote viral RNA synthesis. J. Virol. 2021;95:e0092221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8428400</ArticleId><ArticleId IdType="pubmed">34287048</ArticleId></ArticleIdList></Reference><Reference><Citation>Pécheur EI. Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection. Sci. (Cairo) 2012;2012:709853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820461</ArticleId><ArticleId IdType="pubmed">24278733</ArticleId></ArticleIdList></Reference><Reference><Citation>Esser K, et al. Hepatitis B virus targets lipid transport pathways to infect hepatocytes. Cell Mol. Gastroenterol. Hepatol. 2023;16:201–221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10394270</ArticleId><ArticleId IdType="pubmed">37054914</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei C, et al. HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. Nat. Metab. 2020;2:1391–1400.</Citation><ArticleIdList><ArticleId IdType="pubmed">33244168</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H, et al. Evasion of Type I Interferon by SARS-CoV-2. Cell Rep. 2020;33:108234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7501843</ArticleId><ArticleId IdType="pubmed">32979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C, Anderson P, Hahm B. Viral dedication to vigorous destruction of interferon receptors. Virology. 2018;522:19–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6087481</ArticleId><ArticleId IdType="pubmed">30014854</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarret A, et al. Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. Nat. Med. 2016;22:1475–1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5551900</ArticleId><ArticleId IdType="pubmed">27841874</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. Pseudorabies virus dUTPase UL50 induces lysosomal degradation of Type I interferon Receptor 1 and antagonizes the alpha interferon response. J. Virol. 2017;91:e01148–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5640830</ArticleId><ArticleId IdType="pubmed">28794045</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, et al. Identification of α2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis. Arthritis Rheumatol. 2014;66:1843–1853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4187342</ArticleId><ArticleId IdType="pubmed">24578232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Bu G. Receptor-associated protein interacts with Amyloid-β peptide and promotes its cellular uptake. J. Biol. Chem. 2009;284:33352–33359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785178</ArticleId><ArticleId IdType="pubmed">19826010</ArticleId></ArticleIdList></Reference><Reference><Citation>Cater JH, Wilson MR, Wyatt AR. Alpha-2-Macroglobulin, a hypochlorite-regulated chaperone and immune system modulator. Oxid. Med Cell Longev. 2019;2019:5410657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679887</ArticleId><ArticleId IdType="pubmed">31428227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu M, Zhao B, Wei L, Wang S. alpha-2-Macroglobulin, a native and powerful proteinase inhibitor, prevents cartilage degeneration disease by inhibiting majority of catabolic enzymes and cytokines. Curr. Mol. Biol. Rep. 2021;7:1–7.</Citation></Reference><Reference><Citation>Sato A, Shimada Y, Herz J, Yamamoto T, Jingami H. 39-kDa receptor-associated protein (RAP) facilitates secretion and ligand binding of extracellular region of very-low-density-lipoprotein receptor: implications for a distinct pathway from low-density-lipoprotein receptor. Biochem J. 1999;341:377–383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220370</ArticleId><ArticleId IdType="pubmed">10393096</ArticleId></ArticleIdList></Reference><Reference><Citation>Depboylu C, et al. Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer’s disease. Neurosci. Lett. 2006;400:187–190.</Citation><ArticleIdList><ArticleId IdType="pubmed">16650578</ArticleId></ArticleIdList></Reference><Reference><Citation>Véniant MM, et al. Lipoprotein clearance mechanisms in LDL receptor-deficient “Apo-B48-only” and “Apo-B100-only” mice. J. Clin. Invest. 1998;102:1559–1568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC509006</ArticleId><ArticleId IdType="pubmed">9788969</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddle TM, Schildmeyer NM, Phan C, Fichtenbaum CJ, Hui DY. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J. Lipid Res. 2002;43:1458–1463.</Citation><ArticleIdList><ArticleId IdType="pubmed">12235177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, et al. Attenuating innate immunity and facilitating beta-coronavirus infection by NSP1 of SARS-CoV-2 through specific redistributing hnRNP A2/B1 cellular localization. Signal Transduct. Target Ther. 2021;6:371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8546379</ArticleId><ArticleId IdType="pubmed">34702797</ArticleId></ArticleIdList></Reference><Reference><Citation>Evgin L, et al. Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nat. Commun. 2020;11:3187–3187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314766</ArticleId><ArticleId IdType="pubmed">32581235</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>